Iron and transfusion medicine

Blood Reviews

Volumn 27, Issue 6, 2013, Pages 289-295

  Waldvogel Abramovski, Sophie ^a   Waeber, Gérard ^b   Gassner, Christoph ^c   Buser, Andreas ^d   Frey, Beat M ^c   Favrat, Bernard ^e   Tissot, Jean Daniel ^a  

^a Service Regional Vaudois de Transfusion Sanguine   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Blutspende Zurich   (Switzerland)

^d Blutspende Beiderbasel   (Switzerland)

^e POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

Author keywords

Iron; Iron deficiency anemia; Iron deficiency without anemia; Iron metabolism; Iron overload; Transfusion medicine; Type 2 diabetes

Indexed keywords

FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; PLACEBO; PROTOPORPHYRIN ZINC;

ARTICLE; BIOMEDICINE; BLOOD DONOR; BLOOD TRANSFUSION; CLINICAL PROTOCOL; FATIGUE; FERRITIN BLOOD LEVEL; GENETIC PREDISPOSITION; GENOMICS; GLUCOSE METABOLISM; HEMOCHROMATOSIS; HEMOGLOBIN BLOOD LEVEL; HEMOSIDEROSIS; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON DEPLETION; IRON METABOLISM; IRON STORAGE; IRON THERAPY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHLEBOTOMY; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSFUSION MEDICINE;

GENOME WIDE ASSOCIATION STUDIES; GWAS; HB; HEMOGLOBIN; HEREDITARY HEMOCHROMATOSIS; HH; IDWA; IRON; IRON DEFICIENCY ANEMIA; IRON DEFICIENCY WITHOUT ANEMIA; IRON METABOLISM; IRON OVERLOAD; NASH; NONALCOHOLIC FATTY LIVER DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; SOLUBLE TRANSFERRIN RECEPTOR; STFR; T2D; TRANSFUSION MEDICINE; TYPE 2 DIABETES; ZINC PROTOPORPHYRIN; ZPP;

ANEMIA, IRON-DEFICIENCY; ANIMALS; BLOOD DONORS; BLOOD TRANSFUSION; HUMANS; IRON; TRANSFUSION MEDICINE;

EID: 84887611789     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.10.001     Document Type: Article

References (117)

1. O'Meara A., Infanti L., Sigle J., Stern M., Buser A. Switching iron-deficient whole blood donors to plateletpheresis. Transfusion 2012, 52:2183-2188.
2. Stern M., O'Meara A., Infanti L., Sigle J.P., Buser A. Prognostic value of red blood cell parameters and ferritin in predicting deferral due to low hemoglobin in whole blood donors. Ann Hematol 2012, 91:775-780.
3. O'Meara A., Infanti L., Stebler C., Ruesch M., Sigle J.P., Stern M., et al. The value of routine ferritin measurement in blood donors. Transfusion 2011, 51:2183-2188.
4. Waldvogel S., Pedrazzini B., Vaucher P., Bize R., Cornuz J., Tissot J.D., et al. Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial. BMC Med 2012, 10:8.
5. Pasricha S.R., McQuilten Z.K., Keller A.J., Wood E.M. Hemoglobin and iron indices in nonanemic premenopausal blood donors predict future deferral from whole blood donation. Transfusion 2011, 51:2709-2713.
6. Cable R.G., Glynn S.A., Kiss J.E., Mast A.E., Steele W.R., Murphy E.L., et al. Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion 2012, 52:702-711.
7. Rosvik A.S., Ulvik R.J., Wentzel-Larsen T., Hervig T. The effect of blood donation frequency on iron status. Transfus Apher Sci 2009, 41:165-169.
8. Flesland O., Eskelund A.K., Flesland A.B.., Falch D., Solheim B.G., Seghatchian J. Transferrin receptor in serum. A new tool in the diagnosis and prevention of iron deficiency in blood donors. Transfus Apher Sci 2004, 31:11-16.
9. Pasricha S.R., McQuilten Z., Westerman M., Keller A., Nemeth E., Ganz T., et al. Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors. Haematologica 2011, 96:1099-1105.
10. Verdon F., Burnand B., Stubi C.L., Bonard C., Graff M., Michaud A., et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 2003, 326:1124.
11. Favrat B., Waldvogel Abramowski S., Vaucher P., Cornuz J., Tissot J.D. Iron deficiency without anemia: where are we in 2012?. Rev Med Suisse 2012, 8:2277-2278. [80-1].
12. Vaucher P., Druais P.L., Waldvogel S., Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ 2012, 184:1247-1254.
13. Goddard A.F., James M.W., McIntyre A.S., Scott B.B. Guidelines for the management of iron deficiency anaemia. Gut 2011, 60:1309-1316.
14. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J.L. Measuring the global burden of disease and risk factors, 1990-2001. Global burden of disease and risk factors 2006, World Bank, Washington (DC). A.D. Lopez, C.D. Mathers, M. Ezzati, D.T. Jamison, C.J.L. Murray (Eds.).
15. von Drygalski A., Adamson J.W. Ironing out fatigue. Blood 2011, 118:3191-3192.
16. Falkingham M., Abdelhamid A., Curtis P., Fairweather-Tait S., Dye L., Hooper L. The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis. Nutr J 2010, 9:4.
17. Vazquez Martinez C., Galan P., Preziosi P., Ribas L., Serra L.L., Hercberg S. The SUVIMAX (France) study: the role of antioxidants in the prevention of cancer and cardiovascular disorders. Rev Esp Salud Publica 1998, 72:173-183.
18. Cogswell M.E., Looker A.C., Pfeiffer C.M., Cook J.D., Lacher D.A., Beard J.L., et al. Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003-2006. Am J Clin Nutr 2009, 89:1334-1342.
19. Beutler E., Larsh S.E., Gurney C.W. Iron therapy in chronically fatigued, nonanemic women: a double-blind study. Ann Intern Med 1960, 52:378-394.
20. Favrat B., Gasche C., Hedenus M., Mezzacasa A., Küng C. One 1000mg iron dose of ferric carboxymaltose improved fatigue in iron-deficient, non-anaemic women in the randomised placebo-controlled study PREFER. BJOG 2012, 119:232-233.
21. Brownlie Tt, Utermohlen V., Hinton P.S., Haas J.D. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004, 79:437-443.
22. Friedmann B., Weller E., Mairbaurl H., Bartsch P. Effects of iron repletion on blood volume and performance capacity in young athletes. Med Sci Sports Exerc 2001, 33:741-746.
23. Trenkwalder C., Paulus W., Walters A.S. The restless legs syndrome. Lancet Neurol 2005, 4:465-475.
24. Rasmussen K. Is there a causal relationship between iron deficiency or iron-deficiency anemia and weight at birth, length of gestation and perinatal mortality?. J Nutr 2001, 131:590S-601S. [discussion S-3S].
25. Anker S.D., Comin Colet J., Filippatos G., Willenheimer R., Dickstein K., Drexler H., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009, 361:2436-2448.
26. Newman B. Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed. Transfusion 2006, 46:1667-1681.
27. Cancado R.D., Langhi D. Blood donation, blood supply, iron deficiency and anemia-it is time to shift attention back to donor health. Rev Bras Hematol Hemoter 2012, 34:330-331.
28. Milman N., Byg K.E., Ovesen L., Kirchhoff M., Jurgensen K.S. Iron status in Danish men 1984-94: a cohort comparison of changes in iron stores and the prevalence of iron deficiency and iron overload. Eur J Haematol 2002, 68:332-340.
29. Hallberg L., Hulten L., Gramatkovski E. Iron absorption from the whole diet in men: how effective is the regulation of iron absorption?. Am J Clin Nutr 1997, 66:347-356.
30. Baart A.M., van Noord P.A., Vergouwe Y., Moons K.G., Swinkels D.W., Wiegerinck E.T., et al. High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin. Transfusion 2012, 2012:1537-2995.
31. Mast A.E., Foster T.M., Pinder H.L., Beczkiewicz C.A., Bellissimo D.B., Murphy A.T., et al. Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008, 48:2197-2204.
32. Frey B.M., Rüfer A., Hardegger K., Bachmann G., Kuhn C., Schmid I., et al. Iron balance remains stable in life-long blood donors. Forum Med Suisse 2007, 7:78 S.
33. Hallberg L., Hulthen L. High serum ferritin is not identical to high iron stores. Am J Clin Nutr 2003, 78:1225-1226.
34. Nemeth E., Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006, 26:323-342.
35. Ganz T. Hepcidin and iron regulation, 10years later. Blood 2011, 117:4425-4433.
36. Robens J. Hepcidin: the link to understanding iron regulation. MLO Med Lab Obs 2010, 42:10. [2, 4; quiz 8-9].
37. Theurl M., Theurl I., Hochegger K., Obrist P., Subramaniam N., van Rooijen N., et al. Kupffer cells modulate iron homeostasis in mice via regulation of hepcidin expression. J Mol Med 2008, 86:825-835.
38. Nicolas G., Chauvet C., Viatte L., Danan J.L., Bigard X., Devaux I., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002, 110:1037-1044.
39. Krijt J., Niederkofler V., Salie R., Sefc L., Pelichovska T., Vokurka M., et al. Effect of phlebotomy on hepcidin expression in hemojuvelin-mutant mice. Blood Cells Mol Dis 2007, 39:92-95.
40. Fleming M.D. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program 2008, 151-158.
41. Schorer G., Brittenham G., Darnuzer R., Westerman M., Frey B.M. Iron balance in repeat blood donors-the role of hepcidin. Transfus Med Hemother 2009, 36:3.05.
42. Mast A.E., Schlumpf K.S., Wright D.J., Johnson B., Glynn S.A., Busch M.P., et al. Hepcidin predicts hemoglobin in individuals experiencing repeated phlebotomy. Haematologica 2013, 2013:26.
43. Rochat B., Peduzzi D., McMullen J., Favre A., Kottelat E., Favrat B., et al. Validation of hepcidin quantification in plasma using LC-HRMS and discovery of a new hepcidin isoform. Bioanalysis 2013, 5:2509-2520.
44. Jacob M., Annaheim S., Boutellier U., Hinske C., Rehm M., Breymann C., et al. Haematocrit is invalid for estimating red cell volume: a prospective study in male volunteers. Blood Transfus 2012, 10:471-479.
45. Cable R.G., Steele W.R., Melmed R.S., Johnson B., Mast A.E., Carey P.M., et al. The difference between fingerstick and venous hemoglobin and hematocrit varies by sex and iron stores. Transfusion 2012, 52:1031-1040.
46. Gayat E., Aulagnier J., Matthieu E., Boisson M., Fischler M. Non-invasive measurement of hemoglobin: assessment of two different point-of-care technologies. PloS one 2012, 7:e30065.
47. Raikhel M. Accuracy of noninvasive and invasive point-of-care total blood hemoglobin measurement in an outpatient setting. Postgrad Med 2012, 124:250-255.
48. da Silva M.A., de Souza R.A., Carlos A.M., Soares S., Moraes-Souza H., Pereira Gde A. Etiology of anemia of blood donor candidates deferred by hematologic screening. Rev Bras Hematol Hemoter 2012, 34:356-360.
49. Booth A.O., Lim K., Capper H., Irving D., Fisher J., McNaughton S.A., et al. Iron status and dietary iron intake of female blood donors. Transfusion 2013, 10.1111/trf.12347.
50. Spencer B.R., Kleinman S., Wright D.J., Glynn S.A., Rye D.B., Kiss J.E., et al. Restless legs syndrome, pica, and iron status in blood donors. Transfusion 2013, 53:1645-1652.
51. EDQM Guide to the preparation. Use and quality assurance of blood components 2011, 16th ed.
52. Kiss J.E., Steele W.R., Wright D.J., Mast A.E., Carey P.M., Murphy E.L., et al. Laboratory variables for assessing iron deficiency in REDS-II Iron Status Evaluation (RISE) blood donors. Transfusion 2013, 10.1111/trf.12209.
53. Bryant B.J., Yau Y.Y., Arceo S.M., Hopkins J.A., Leitman S.F. Ascertainment of iron deficiency and depletion in blood donors through screening questions for pica and restless legs syndrome. Transfusion 2013, 53:1637-1644.
54. Baart A.M., de Kort W.L., Moons K.G., Atsma F., Vergouwe Y. Zinc protoporphyrin levels have added value in the prediction of low hemoglobin deferral in whole blood donors. Transfusion 2013, 53:1661-1669.
55. Baart A.M., de Kort W.L., Atsma F., Moons K.G., Vergouwe Y. Development and validation of a prediction model for low hemoglobin deferral in a large cohort of whole blood donors. Transfusion 2012, 52:2559-2569.
56. Baart A.M., Atsma F., McSweeney E.N., Moons K.G., Vergouwe Y., de Kort W.L. External validation and updating of a Dutch prediction model for low hemoglobin deferral in Irish whole blood donors. Transfusion 2013, 10.1111/trf.12211.
57. Piperno A. Molecular diagnosis of hemochromatosis. Expert Opin Med Diagn 2013, 7:161-177.
58. Santos P.C., Dinardo C.L., Cancado R.D., Schettert I.T., Krieger J.E., Pereira A.C. Non-HFE hemochromatosis. Rev Bras Hematol Hemoter 2012, 34:311-316.
59. Santos P.C., Soares R.A., Krieger J.E., Guerra-Shinohara E.M., Pereira A.C. Genotyping of the hemochromatosis HFE p.H63D and p.C282Y mutations by high-resolution melting with the Rotor-Gene 6000(R) instrument. Clin Chem Lab Med 2011, 49:1633-1636.
60. Santos P.C., Cancado R.D., Pereira A.C., Schettert I.T., Soares R.A., Pagliusi R.A., et al. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients. Blood Cells Mol Dis 2011, 46:302-307.
61. Santos P.C., Cancado R.D., Pereira A.C., Chiattone C.S., Krieger J.E., Guerra-Shinohara E.M. HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox. Acta Haematol 2010, 124:204-205.
62. Pelucchi S., Mariani R., Calza S., Fracanzani A.L., Modignani G.L., Bertola F., et al. CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients. Haematologica 2012, 97:1818-1825.
63. Crownover B.K., Covey C.J. Hereditary hemochromatosis. Am Fam Physician 2013, 87:183-190.
64. Fagiuoli S., Daina E., D'Antiga L., Colledan M., Remuzzi G. Monogenic diseases that can be cured by liver transplantation. J Hepatol 2013, 59:595-612.
65. Carpenter J.P., Grasso A.E., Porter J.B., Shah F., Dooley J., Pennell D.J. On myocardial siderosis and left ventricular dysfunction in hemochromatosis. J Cardiovasc Magn Reson 2013, 15:24.
66. Tirnitz-Parker J.E., Glanfield A., Olynyk J.K., Ramm G.A. Iron and hepatic carcinogenesis. Crit Rev Oncog 2013, 18:391-407.
67. Siddique A., Kowdley K.V. Review article: the iron overload syndromes. Aliment Pharmacol Ther 2012, 35:876-893.
68. Fernandez-Real J.M., Lopez-Bermejo A., Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002, 51:2348-2354.
69. Perez de Nanclares G., Castano L., Gaztambide S., Bilbao J.R., Pi J., Gonzalez M.L., et al. Excess iron storage in patients with type 2 diabetes unrelated to primary hemochromatosis. N Engl J Med 2000, 343:890-891.
70. Simcox J.A., McClain D.A. Iron and diabetes risk. Cell Metab 2013, 17:329-341.
71. McClain D.A., Abraham D., Rogers J., Brady R., Gault P., Ajioka R., et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 2006, 49:1661-1669.
72. Cooksey R.C., Jones D., Gabrielsen S., Huang J., Simcox J.A., Luo B., et al. Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep-/-) mouse. Am J Physiol Endocrinol Metab 2010, 298:E1236-E1243.
73. Hatunic M., Finucane F.M., Brennan A.M., Norris S., Pacini G., Nolan J.J. Effect of iron overload on glucose metabolism in patients with hereditary hemochromatosis. Metab Clin Exp 2010, 59:380-384.
74. Abraham D., Rogers J., Gault P., Kushner J.P., McClain D.A. Increased insulin secretory capacity but decreased insulin sensitivity after correction of iron overload by phlebotomy in hereditary haemochromatosis. Diabetologia 2006, 49:2546-2551.
75. Opara E.C. Role of oxidative stress in the etiology of type 2 diabetes and the effect of antioxidant supplementation on glycemic control. J Invest Med 2004, 52:19-23.
76. Jouihan H.A., Cobine P.A., Cooksey R.C., Hoagland E.A., Boudina S., Abel E.D., et al. Iron-mediated inhibition of mitochondrial manganese uptake mediates mitochondrial dysfunction in a mouse model of hemochromatosis. Mol Med 2008, 14:98-108.
77. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23:599-622.
78. Bao W., Rong Y., Rong S., Liu L. Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis. BMC Med 2012, 10:119.
79. Zhao Z., Li S., Liu G., Yan F., Ma X., Huang Z., et al. Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis. PloS one 2012, 7:e41641.
80. Forouhi N.G., Harding A.H., Allison M., Sandhu M.S., Welch A., Luben R., et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 2007, 50:949-956.
81. Fumeron F., Pean F., Driss F., Balkau B., Tichet J., Marre M., et al. Ferritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3years: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes Care 2006, 29:2090-2094.
82. Jiang R., Manson J.E., Meigs J.B., Ma J., Rifai N., Hu F.B. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004, 291:711-717.
83. Kunutsor S.K., Apekey T.A., Walley J., Kain K. Ferritin levels and risk of type 2 diabetes mellitus: an updated systematic review and meta-analysis of prospective evidence. Diabetes Metab Res Rev 2013, 29:308-318.
84. Tanaka T., Roy C.N., Yao W., Matteini A., Semba R.D., Arking D., et al. A genome-wide association analysis of serum iron concentrations. Blood 2010, 115:94-96.
85. Gan W., Guan Y., Wu Q., An P., Zhu J., Lu L., et al. Association of TMPRSS6 polymorphisms with ferritin, hemoglobin, and type 2 diabetes risk in a Chinese Han population. Am J Clin Nutr 2012, 95:626-632.
86. Minamiyama Y., Takemura S., Kodai S., Shinkawa H., Tsukioka T., Ichikawa H., et al. Iron restriction improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. Am J Physiol Endocrinol Metab 2010, 298:E1140-E1149.
87. Fernandez-Real J.M., Lopez-Bermejo A., Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion. Clin Chem 2005, 51:1201-1205.
88. Hatunic M., Finucane F.M., Norris S., Pacini G., Nolan J.J. Glucose metabolism after normalization of markers of iron overload by venesection in subjects with hereditary hemochromatosis. Metab Clin Exp 2010, 59:1811-1815.
89. Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes 1989, 38:1207-1210.
90. Fernandez-Real J.M., Penarroja G., Castro A., Garcia-Bragado F., Hernandez-Aguado I., Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002, 51:1000-1004.
91. Facchini F.S. Effect of phlebotomy on plasma glucose and insulin concentrations. Diabetes Care 1998, 21:2190.
92. Fernandez-Real J.M., Penarroja G., Castro A., Garcia-Bragado F., Lopez-Bermejo A., Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. Diabetes Care 2002, 25:2249-2255.
93. Facchini F.S., Hua N.W., Stoohs R.A. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002, 122:931-939.
94. Zacharski L.R., Chow B.K., Howes P.S., Shamayeva G., Baron J.A., Dalman R.L., et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 2007, 297:603-610.
95. De Domenico I., McVey Ward D., Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol 2008, 9:72-81.
96. Kaplan J., Ward D.M., De Domenico I. The molecular basis of iron overload disorders and iron-linked anemias. Int J Hematol 2011, 93:14-20.
97. Pantopoulos K., Porwal S.K., Tartakoff A., Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry 2012, 51:5705-5724.
98. Ramsay A.J., Quesada V., Sanchez M., Garabaya C., Sarda M.P., Baiget M., et al. Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms. Hum Mol Genet 2009, 18:3673-3683.
99. Ramsay A.J., Hooper J.D., Folgueras A.R., Velasco G., Lopez-Otin C. Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis. Haematologica 2009, 94:840-849.
100. Hercberg S., Preziosi P., Galan P. Iron deficiency in Europe. Public Health Nutr 2001, 4:537-545.
101. Lee P., Gelbart T., West C., Halloran C., Beutler E. Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol Dis 2002, 29:471-487.
102. Ribas G., Gonzalez-Neira A., Salas A., Milne R.L., Vega A., Carracedo B., et al. Evaluating HapMap SNP data transferability in a large-scale genotyping project involving 175 cancer-associated genes. Hum Genet 2006, 118:669-679.
103. Gu C.C., Flores H.R., de las Fuentes L., Davila-Roman V.G. Enhanced detection of genetic association of hypertensive heart disease by analysis of latent phenotypes. Genet Epidemiol 2008, 32:528-538.
104. Pajukanta P., Peltonen L. How to tackle genetic loci predisposing to atherosclerosis?. Curr Opin Lipidol 1997, 8:95-100.
105. Gurling H. Application of molecular biology to mental illness. Analysis of genomic DNA and brain mRNA. Psychiatr Dev 1985, 3:257-273.
106. Kwon J.M., Goate A.M. The candidate gene approach. Alcohol Res Health 2000, 24:164-168.
107. Tang K., Fu D., Kotter S., Cotter R.J., Cantor C.R., Koster H. Matrix-assisted laser desorption/ionization mass spectrometry of immobilized duplex DNA probes. Nucleic Acids Res 1995, 23:3126-3131.
108. Ding C., Cantor C.R. A high-throughput gene expression analysis technique using competitive PCR and matrix-assisted laser desorption ionization time-of-flight MS. Proc Natl Acad Sci U S A 2003, 100:3059-3064.
109. Docherty S.J., Davis O.S., Haworth C.M., Plomin R., Mill J. DNA methylation profiling using bisulfite-based epityping of pooled genomic DNA. Methods 2010, 52:255-258.
110. Fumagalli D., Gavin P.G., Taniyama Y., Kim S.I., Choi H.J., Paik S., et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 2010, 10:101.
111. Meyer K., Ueland P.M. Use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for multiplex genotyping. Adv Clin Chem 2011, 53:1-29.
112. Millis M.P. Medium-throughput SNP, genotyping using mass spectrometry: multiplex SNP genotyping using the iPLEX(R) Gold assay. Methods Mol Biol 2011, 700:61-76.
113. Oeth P., del Mistro G., Marnellos G., Shi T., van den Boom D. Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY). Methods Mol Biol 2009, 578:307-343.
114. Gassner C., Meyer S., Frey B.M., Vollmert C. Matrix-assisted laser desorption/ionisation, time-of-flight mass spectrometry-based blood group genotyping-the alternative approach. Transfus Med Rev 2013, 27:2-9.
115. Cordell H.J. Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 2009, 10:392-404.
116. Wan X., Yang C., Yang Q., Xue H., Fan X., Tang N.L., et al. BOOST: a fast approach to detecting gene-gene interactions in genome-wide case-control studies. Am J Hum Genet 2010, 87:325-340.
117. Zhu Z., Tong X., Zhu Z., Liang M., Cui W., Su K., et al. Development of GMDR-GPU for gene-gene interaction analysis and its application to WTCCC GWAS data for type 2 diabetes. PloS one 2013, 8:e61943.